Gritstone bio (GRTS)
(Real Time Quote from BATS)
$0.66 USD
0.00 (0.49%)
Updated Jul 26, 2024 11:16 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GRTS 0.66 0.00(0.49%)
Will GRTS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GRTS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GRTS
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
GRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
Other News for GRTS
Gritstone to host KOL event to discuss GRANITE cancer vaccine program
Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Gritstone Oncology (GRTS) and Clene (CLNN)
Forecasting The Future: 4 Analyst Projections For Gritstone Bio